Liabilities Breakdown
Current Liabilities
79.5 M
Long-Term Liabilities
| Total Liabilities | 97.67 Million | |
| Current Liabilities | 6.66 Million | |
| Long-Term Liabilities | 79.51 Million |
Should I hold on to my Recro (NASDAQ:REPH) position?
 | By Rifka Kats | Macroaxis Story |
The next fiscal quarter end is expected on the 31st of December 2020. The stock goes through an active upward rally. Recro Pharma Tangible Asset Value is most likely to increase significantly in the upcoming years. The preceding year's Tangible Asset Value was reported at 83.01 Million. The current Working Capital is estimated to increase to about 28.3 M, while Net Income Per Employee is projected to decrease to (93.5 K). While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to concentrate on Recro Pharma as an investment alternative.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
The company currently holds 118.39 M in liabilities with Debt to Equity (D/E) ratio of 403.6, indicating Recro Pharma may have difficulties to generate enough cash to satisfy its financial obligations. Recro Pharma has a current ratio of 3.87, suggesting that it is liquid enough and is able to pay its financial obligations when due.
How important is Recro Pharma's Liquidity
Recro Pharma financial leverage refers to using borrowed capital as a funding source to finance Recro Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Recro Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Recro Pharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Recro Pharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Recro Pharma's total debt and its cash.
Going after Recro Financials
The entity reported the previous year's revenue of 74.23 M. Net Loss for the year was (20.54 M) with profit before overhead, payroll, taxes, and interest of 48.24 M.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Recro Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.